Representation of Chronic Kidney Disease in Randomized Controlled Trials Among Patients With Heart failure With Reduced Ejection Fraction: A Systematic Review.
Publication/Presentation Date
11-14-2021
Abstract
Patients with advanced chronic kidney disease (CKD) have largely been excluded from randomized control trials (RCTs) in heart failure (HF). This creates a paucity of high quality evidence for guideline directed medical therapy (GDMT), particularly in patients with heart failure with reduced ejection fraction (HFrEF) and CKD. This is a systematic review looking at the patterns and rates of inclusion of CKD in RCTs among patients with HFrEF. The search included RCTs from January 2010 to December 2020. A heat map was constructed to reflect the stages of CKD stages. The percentage of studies that included advanced CKD (stages IV-V) was recorded and log transformed, and then fitted into a time regression model. A P value of
First Page
101047
Last Page
101047
ISSN
1535-6280
Published In/Presented At
Lo, K. B., Essa, H., Wattoo, A., Gulab, A., Akhtar, H., Sudani, H. A., Angelim, L., Helfman, B., Peterson, E., Brousas, S., Whybrow-Huppatz, I., Yazdanyar, A., Sankaranarayanan, R., & Rangaswami, J. (2021). Representation of Chronic Kidney Disease in Randomized Controlled Trials Among Patients With Heart failure With Reduced Ejection Fraction: A Systematic Review. Current problems in cardiology, 101047. Advance online publication. https://doi.org/10.1016/j.cpcardiol.2021.101047
Disciplines
Medicine and Health Sciences
PubMedID
34785259
Department(s)
Department of Emergency Medicine
Document Type
Article